The position of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) raised by AQR Capital Management LLC

AQR Capital Management LLC increased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 92.5% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 271,619 shares of the biopharmaceutical company’s stock after purchasing an additional 130,482 shares during the quarter. AQR Capital Management LLC owned approximately 0.21% of Alnylam Pharmaceuticals worth $65,862,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the company. Allspring Global Investments Holdings LLC raised its stake in Alnylam Pharmaceuticals by 572.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 143 shares in the last quarter. Ashton Thomas Private Wealth LLC purchased a new stake in Alnylam Pharmaceuticals in the second quarter valued at about $26,000. Altitude Crest Partners Inc. bought a new position in shares of Alnylam Pharmaceuticals in the first quarter valued at about $30,000. V Square Quantitative Management LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at about $52,000. Finally, Prestige Wealth Management Group LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 69.8% in the first quarter. Prestige Wealth Management Group LLC now owns 472 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 194 shares in the last quarter. 92.97% of shares are currently held by institutional investors and hedge funds.

Insider buying and selling

In other Alnylam Pharmaceuticals news, Director Dennis A. Ausiello sold 20,250 shares of the company’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the completion of the transaction, the director now owns 136 shares of the company’s stock, valued at approximately $35,632. The transaction was disclosed in a filing with the SEC, which can be accessed via this hyperlink. In related news, CEO Yvonne Greenstreet sold 15,148 shares of the business’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $270.00, for a total transaction of $4,089,960.00. Following the transaction, the chief executive officer now owns 73,441 shares of the company’s stock, valued at $19,829,070. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Dennis A. Ausiello sold 20,250 shares of the business’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the transaction, the director now owns 136 shares of the company’s stock, valued at $35,632. The disclosure for this sale can be found here. Over the last three months, insiders have sold 57,491 shares of company stock worth $15,446,733. Company insiders own 1.50% of the company’s shares.

Alnylam Pharmaceuticals price performance

Shares of Alnylam Pharmaceuticals opened at $274.91 on Friday. Alnylam Pharmaceuticals, Inc. it has a one year low of $141.98 and a one year high of $287.55. The company’s fifty day moving average price is $263.00 and its two hundred day moving average price is $203.01. The company has a market cap of $34.77 billion, a price-to-earnings ratio of -102.58 and a beta of 0.38.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report ) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.61. The company had revenue of $659.83 million during the quarter, compared to the consensus estimate of $447.22 million. The company’s revenue increased by 107.0% year-on-year. In the same period last year, the company posted ($2.21) earnings per share. As a group, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.73 earnings per share for the current year.

Analysts set new price targets

ALNY has been the subject of a number of research reports. TD Cowen boosted their target price on shares of Alnylam Pharmaceuticals from $260.00 to $282.00 and gave the stock a “buy” rating in a report on Tuesday, June 25th. Citigroup upped their price target on Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Evercore ISI upped their target price on Alnylam Pharmaceuticals from $210.00 to $260.00 and gave the company an “outperform” rating in a research report on Tuesday, June 25th. Bank of America boosted their price objective on Alnylam Pharmaceuticals from $295.00 to $307.00 and gave the stock a “buy” rating in a report on Wednesday, September 4th. Finally, BMO Capital Markets reiterated an “outperform” rating and issued a $234.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, June 24th. Seven investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $279.14.

Check out our latest stock analysis on Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Profile

(Free Report)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, is focused on the discovery, development and commercialization of novel ribonucleic acid interference-based therapies. Its marketed products include ONPATTRO (patisiran) for the treatment of transthyretin-mediated polyneuropathy of hereditary amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Read more

Get daily news and reviews for Alnylam Pharmaceuticals – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.